---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-120557"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-11-22T23:59:59+00:00"
generated_at: "2026-06-07T22:16:45.352662+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Entrada completes first two cohorts in Phase 1 for ENTR-601-44; US clinical hold remains

## Summary
- Completed dosing of first and second cohorts in Phase 1 trial ENTR-601-44-101 in the UK.
- Data from Phase 1 trial expected in second half of 2024.
- FDA clinical hold on IND remains in effect; FDA declined to lift hold despite additional data.
- Company plans global development for exon 44 skipping amenable DMD patients.
- Cash runway expected through 2025.

## SEC filing metadata
- accession: 0001104659-23-120557
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465923120557/0001104659-23-120557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465923120557/tm2331388d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-120557
- JSON: https://secwatch.observer/filing/0001104659-23-120557.json
- Plain text: https://secwatch.observer/filing/0001104659-23-120557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.